{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-013866","form_type":"8-K","ticker":"APLS","cik":"0001492422","company_name":"Apellis Pharmaceuticals, Inc.","filed_at":"2022-01-20T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.703750+00:00","generated_at":"2026-06-27T16:47:53.821339+00:00","sec_items":["1.01","1.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Apellis enters $300M at-the-market equity offering with Jefferies LLC","bullets":["Apellis may sell up to $300M common stock in at-the-market offerings through Jefferies LLC.","Jefferies receives commission of up to 3% of gross proceeds for acting as sales agent.","Prior $150M equity distribution agreement with Citigroup and Jefferies terminated.","Shares sold under existing automatic shelf registration statement effective Jan 2020."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-013866","json":"https://secwatch.observer/filing/0001193125-22-013866.json","markdown":"https://secwatch.observer/filing/0001193125-22-013866.md","text":"https://secwatch.observer/filing/0001193125-22-013866.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1492422/000119312522013866/0001193125-22-013866-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1492422/000119312522013866/d277809d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T16:47:53.821339+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}